Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

475.41 +1.59 (+0.34%)
Streaming Delayed Price Updated: 12:57 PM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
43 44 Next >
Kymera Therapeutics Stock Scores Rising Relative Price Strength
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $13,000 Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 6.35% on an annualized basis producing an average annual return of 14.14%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
Devon Energy, Eli Lilly Are CNBC 'Fast Money' Mentions, With Kevin O'Leary Selling These 7 Stocks
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. 
Via Benzinga
This Analyst Boosts Price Target On Home Depot Following Strong Earnings, Plus Citigroup Slashes PT On This Stock By Over 60%
Baird boosted the price target for The Home Depot, Inc. (NYSE: HD) from $335 to $360. Home Depot shares fell 0.2% to $326.58 in pre-market trading. 
Via Benzinga
Where Vertex Pharmaceuticals Stands With Analysts
Vertex Pharmaceuticals (NASDAQ:VRTX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Vertex Pharma Easily Beats Quarterly Forecasts And Raises 2022 Outlook
The company noted it's achieving uptake in regions where Trikafta is now reimbursed. 
Via Investor's Business Daily
3 Best Funds for Aggressive Investors
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94. 
Via Investor's Business Daily
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
Via Benzinga
Peering Into Vertex Pharmaceuticals Recent Short Interest
Vertex Pharmaceuticals' (NASDAQ:VRTX) short percent of float has risen 13.71% since its last report. The company recently reported that it has 3.59 million shares... 
Via Benzinga
Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch
Vertex Pharmaceuticals headlines five stocks to watch this week. 
Via Investor's Business Daily
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 7.01% on an annualized basis producing an average annual return of 18.39%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
Vertex Pharmaceuticals: Q2 Earnings Insights
Vertex Pharmaceuticals (NASDAQ:VRTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Oil Falls Amid Rise In Reserves, China Is Creating A Blockade On Taiwan
Crude oil inventories unexpectedly rose by 4.5 million barrels last week, compared to analysts' forecast of 600,000 barrels. The OPEC+ group said it would raise its oil production target by just... 
Via Talk Markets
These 4 Key Sectors Can Be Especially Profitable In A Rising Interest Rate Environment
With record inflation, the Federal Reserve has drastically raised interest rates from 0.25% to 1.75% over the course of the year. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Stocks for Beginners to Buy Now
Here are seven of the best stocks for beginners to buy now, including BP, Visa and Disney.. They can make excellent long-term investments. 
Via InvestorPlace
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has fallen 7.46% since its last report. The company recently reported that it has 3.15 million shares sold short,... 
Via Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
CNBC's Final Trades: Foot Locker, Vertex Pharmaceuticals And This Investment Management Company
On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management said her mentor once told her that “one bets against the U.S. at one’s own peril.” She added to this saying,... 
Via Benzinga
Verve Therapeutics, Vertex Join Forces For Liver Disease-Focused Gene Program
Via Benzinga
Goldman Sachs, Costco Get CNBC Fast Money Mentions, With This Stock Jumping 0.66% In Seconds
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. 
Via Benzinga
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 9.04% on an annualized basis producing an average annual return of 15.59%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
Prometheus Biosciences Stock Shows Rising Relative Strength
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90. 
Via Investor's Business Daily
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
43 44 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.